- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALN-RSV01, normal saline
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 10
- States / cities
- San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Viral Pneumonia
- Interventions
- SNG001, Placebo
- Drug
- Lead sponsor
- Synairgen Research Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more
- Conditions
- Dysphagia
- Interventions
- Fiberoptic Endoscopic Evaluation of Swallowing, Videofluoroscopic Swallowing Study, Voluntary Peak Cough Flow Testing, Iowa Oral Performance Instrument, Capsaicin Challenge, Pulmonary Function Testing, Voicing Tasks
- Procedure · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract Disease
- Interventions
- Siltuximab, Normal Saline
- Drug · Other
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Lansing, Michigan • Charlotte, North Carolina
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Blood And Marrow Transplantation, Adult Respiratory Distress Syndrome
- Interventions
- Mesenchymal Stem Cells (MSCs)
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Influenza A H3N2, Influenza A H1N1
- Interventions
- FLU-IGIV, Placebo for FLU-IGIV
- Biological · Other
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more
- Conditions
- Respiratory Distress Syndrome, Newborn
- Interventions
- #1 Respiratory Care Solution
- Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- Ogden, Utah • Salt Lake City, Utah
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Covid19
- Interventions
- Questionnaires and Patient Reported Outcomes (PROs), Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR), Blood Samples for Biomarkers, High Resolution Computed Tomography, Physical Exam and Vital Signs, Medical Research Council Sum Score, Hand Grip Strength, Spirometry, Diffusing Capacity of Carbon Monoxide, 6 Minute Walk Test, Sit to Stand (STS) Measurement
- Other · Diagnostic Test · Genetic
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • New York, New York • Houston, Texas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT vaccine, dTpa vaccine
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Years to 49 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Beaumont, Texas
- Conditions
- COVID-19
- Interventions
- Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
- Biological · Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
- Conditions
- Rhinovirus
- Interventions
- Nasal Swab Healthy Surveillance, Nasal Swab Sick Samples, Nasal Swab Hospitalized Cohort, Sick Follow-up Survey, Older Cohort Control Group, Procedural Comfort or Care
- Diagnostic Test · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 670 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Albuterol Sulfate, Mini-Bronchoalveolar Lavage (BAL), Placebo
- Drug · Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 40
- States / cities
- Fresno, California • Sacramento, California • San Francisco, California + 19 more
- Conditions
- Critical Illness, Pediatrics, General Surgery, Fluid Therapy, Wounds and Injuries
- Interventions
- Balanced crystalloid solution volume administration, Packed Erythrocytes Units, Blood Product Unit volume, Plasma volume, Platelets volume
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 6 Months to 15 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 4
- States / cities
- Buffalo, New York • New York, New York • Rochester, New York + 1 more